Hydrogen Water Prevents Fatty Liver Disease and Liver Cancer in Mice
- Authors
- Daisuke Kawai, Akinobu Takaki, Atsuko Nakatsuka, Jun Wada, Naofumi Tamaki, Tetsuya Yasunaka, Kazuko Koike, Ryuichiro Tsuzaki, Kazuyuki Matsumoto, Yasuhiro Miyake, Hidenori Shiraha, Manabu Morita, Hirofumi Makino, Kazuhide Yamamoto
- Journal
- Hepatology
- Year
- 2012
- DOI
- 10.1002/hep.25782
- Study Type
- Mouse
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- Japan
- Health Condition
- Non-alcoholic Steatohepatitis (NASH)
- Body System
- Hepatic
TL;DR
Drinking hydrogen-rich water or taking the drug pioglitazone can reduce liver damage and tumor growth in mice with a disease similar to human fatty liver disease.
Key Finding
In mouse models of fatty liver disease and liver cancer, hydrogen-rich water reduced liver inflammation, oxidative stress markers, and tumor development with effects comparable to or stronger than pioglitazone, a standard pharmaceutical treatment.
Summary
Researchers tested whether hydrogen-rich water could help prevent liver damage in mice with nonalcoholic steatohepatitis (NASH), a serious liver condition caused by fat buildup. They fed mice a diet that causes NASH and gave some groups hydrogen-rich water while others received regular water or a drug called pioglitazone. Hydrogen-rich water reduced markers of liver damage, inflammation, and oxidative stress (harmful molecules that damage cells) similarly to or better than the drug. In a second experiment using mice prone to developing liver cancer from NASH, hydrogen-rich water also reduced the number and size of tumors that formed.
Practical Takeaway
While these results are promising, they come from mouse studies only and have not been tested in humans. The findings suggest hydrogen-rich water may help protect against liver damage through antioxidant effects, but much more research—including human clinical trials—is needed before any health claims can be made. Anyone with liver disease should consult their doctor before trying hydrogen water as a supplement.
Abstract
Oxidative stress is a strong contributor to the progression from simple fatty liver to nonalcoholic steatohepatitis (NASH). Molecular hydrogen is an effective antioxidant that reduces cytotoxic reactive oxygen species. In this study, we investigated the effects of hydrogen-rich water and the drug pioglitazone on the progression of NASH in mouse models. A methionine-choline–deficient (MCD) diet mouse model was prepared. Mice were divided into three experimental groups and fed for 8 weeks as follows: (1) MCD diet + control water (CW group); (2) MCD diet + hydrogen-rich water (HW group); and (3) MCD diet mixed with pioglitazone (PGZ group). Plasma alanine aminotransferase levels, hepatic expression of tumor necrosis factor-α, interleukin-6, fatty acid synthesis–related genes, oxidative stress biomarker 8-hydroxydeoxyguanosine (8-OHdG), and apoptosis marker terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling (TUNEL)–positive cells in the liver were decreased in the HW and PGZ groups. The HW group showed a smaller decrease in hepatic cholesterol; however, stronger antioxidative effects in serum and lower peroxisome proliferator-activated receptor-α expression in the liver were seen in comparison with the PGZ group. We then investigated the effects of hydrogen in the prevention of hepatocarcinogenesis in STAM mice, known as the NASH-related hepatocarcinogenesis model. Eight-week-old male STAM mice were divided into three experimental groups as follows: (1) control water (CW-STAM); (2) hydrogen-rich water (HW-STAM); and (3) pioglitazone (PGZ-STAM). After 8 weeks, hepatic tumors were evaluated. The number of tumors was significantly lower in the HW-STAM and PGZ-STAM groups than in the CW-STAM group. The maximum tumor size was smaller in the HW-STAM group than in the other groups. Conclusion: Consumption of hydrogen-rich water may be an effective treatment for NASH by reducing hepatic oxidative stress, apoptosis, inflammation, and hepatocarcinogenesis.